A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.
For this proof-of-principle study, researchers at the UCL Great Ormond Street Institute for Child Health (GOS ICH) and the UCL Cancer Institute modified the patient's own T-cells (a type of immune cell), equipping them to recognize and kill neuroblastoma tumor cells.
Twelve children with relapsed or refractory (where the disease does not respond to treatment) neuroblastoma were treated as part of the Cancer Research UK-funded phase I clinical trial.
The research, published in Science Translational Medicine, is one of the first studies to demonstrate CAR T-cells achieving rapid regression against a solid cancer (non-blood cancer). Although the beneficial effects only lasted a short while, the study provides important evidence that this specific CAR T-cell treatment could be used as a future treatment for children with solid cancers.
Neuroblastoma is a rare type of cancer that mostly affects babies and young children and develops from specialized nerve cells (neuroblasts) left behind from a baby's development in the womb.
Up to 100 children in the UK are diagnosed with neuroblastoma each year. Current treatment for children with an aggressive type of neuroblastoma includes surgical removal, chemotherapy with stem-cell transplant, radiotherapy and antibody therapy. Despite this intensive treatment long-term survival is between 50-60 per cent.
In CAR T-cell therapy, a type of immunotherapy, T-cells are engineered to contain a molecule called a chimeric antigen receptor (CAR) on their surface which can specifically recognize cancerous cells.
For this study the patients' own T-cells were modified with a CAR to target the GD2 surface protein, which is highly abundant on almost all neuroblastoma cells, but found at very low levels in healthy cells.
Researchers found that when using a sufficient dose of the modified CAR T-cells, this treatment induced rapid reduction in tumor size in some of the patients treated. These effects were transient. Importantly, in all patients the CAR T-cells did not cause any harmful side effects in healthy tissues that express the GD2 molecule.
Lead author, Dr Karin Straathof, Research group leader at UCL GOS ICH and Consultant Paediatric Oncologist at Great Ormond Street Hospital NHS Trust said: "It's encouraging to see the anti-tumor activity induced by these modified T-cells in some of the patients on this study.
"While the anti-tumor activity seen was only transient, it provides an important proof-of-principle that CAR T-cells directed at the GD2 molecule could be used against solid cancers in children.
"New treatments are needed for high-risk neuroblastoma and with more research we hope to develop this further into a treatment that results in lasting responses and increases the number of patients that can be cured."
Targeting of solid cancers by CAR T-cells is dependent on their infiltration and expansion within the tumor microenvironment, and thus far fewer clinical responses have been reported.
The rapid regression in neuroblastoma cells is promising, particularly as this activity was observed in the absence of neurotoxicity which occurs with antibody-based approaches that target GD2."
Dr Martin Pule, Senior Author, UCL Cancer Institute
Dr Pule added: "Targeting neuroblastoma with GD2 CAR T-cells appears to be a valid and safe strategy but requires further modification to promote CAR T-cell longevity."
Dr Sue Brook, medical advisor at Cancer Research UK, said: "Children who have hard to treat cancers like neuroblastoma have limited treatment options open to them, especially when the cancer returns.
"The early results for the GD2 CAR-T treatment look promising, especially due to the initial safety data. However more work is needed on making the response last longer, and we are looking forward to seeing the next steps in its development."
The research team are preparing for their next clinical study in collaboration with Autolus, a clinical-stage biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer. This study will evaluate AUTO6NG, which builds on this approach utilising the same GD2 CAR alongside additional programming modules designed to enhance efficacy and persistence.
Straathof, K., et al. (2020) Antitumor activity without on-target off-tumor toxicity of GD2chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine. doi.org/10.1126/scitranslmed.abd6169.
- BCH-BB694 Gene Therapy Safely Treating Severe SCD Patients in... - Sickle Cell Anemia News - January 17th, 2021
- Stem cells on the ballot - Science Magazine - January 16th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 16th, 2021
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 16th, 2021
- Stem cells with regenerative abilities could be closer on the horizon, shows study - News-Medical.net - January 16th, 2021
- Center for cell and gene therapy to open next year - Harvard Gazette - January 16th, 2021
- Study: Retinal stem cells from cadavers may help restore vision in blind - UPI News - January 16th, 2021
- Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic... - January 16th, 2021
- Bone Therapeutics and Rigenerand sign partnership for cell therapy process development - GlobeNewswire - January 16th, 2021
- Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative... - January 16th, 2021
- News briefing: Precision Medicine Group acquires cell and gene therapy-focused services firm Project Farma; RoosterBio and Sartorius collab on gene... - January 16th, 2021
- Mutations in Gene Linked to Acute Myeloid Leukemia Can Drive Other Blood Disorders - Clinical OMICs News - January 16th, 2021
- Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire - January 10th, 2021
- Doctors Make Medical Breakthrough In Treating Severe Cases Of COVID - CBS Denver - January 10th, 2021
- Human Embryonic Stem Cell hESC Market is Booming Worldwide with Types of Players Like Astellas Institute of Regenerative Medicine (US), Asterias... - January 10th, 2021
- Chemicals in e-cigarettes disrupt the gut barrier and trigger inflammation - News-Medical.Net - January 10th, 2021
- Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz Regenerative... - January 3rd, 2021
- Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz Personalized Cellular Immunotherapy in Preclinical Model -... - December 30th, 2020
- ImmCelz, CaverStem, StemSpine; the Run on Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) - MicroCap Daily - December 30th, 2020
- BCL11A Inhibition to Induce Fetal Hemoglobin Shows Promise in Sickle Cell Disease - Hematology Advisor - December 30th, 2020
- ViviGen Cellular Bone Matrix outperforms MSC-based allografts and is equivalent to gold standard autograft - PRNewswire - December 30th, 2020
- Study clarifies the effect of aging on hematopoietic stem cells - News-Medical.net - December 27th, 2020
- Modulating BST2 expression on blood stem cells may help regulate cell activation during chronic infections - News-Medical.Net - December 27th, 2020
- CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications - Targeted Oncology - December 27th, 2020
- Post-doctoral Research Officer Job at Children's Medical Research Institute in Sydney, Australia - The Conversation AU - December 27th, 2020
- Six Benefits of All-on-4 Implants Compared to Regular Dentures - Magazine of Santa Clarita - December 27th, 2020
- Athersys (ATHX) and UTHealth Begin Patient Enrollment in Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma - StreetInsider.com - December 23rd, 2020
- Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health - News@UofT - December 23rd, 2020
- Robert Gallo of the UM School of Medicine Institute of Human Virology and Global Virus Network Awarded Top Life Sciences and Medicine Prize from China... - December 23rd, 2020
- Leaders in stem cell science, regenerative medicine ... - December 18th, 2020
- Stem Cell & Regenerative Medicine Market By Covid-19 ... - December 18th, 2020
- Skandalaris LEAP winners announced | WashU Fuse | Washington University in St. Louis - Washington University in St. Louis Newsroom - December 18th, 2020
- Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using... - December 18th, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 18th, 2020
- Stem cells: Therapy, controversy, and research | Femto ... - December 18th, 2020
- Scientists use human stem cells and bioengineered scaffold to build whole functioning thymus - News-Medical.Net - December 15th, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 15th, 2020
- CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - BioSpace - December 15th, 2020
- CollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications - PRNewswire - December 15th, 2020
- Cell Isolation/ Separation Market worth $15.0 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire - December 15th, 2020
- Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Country -... - December 7th, 2020
- Treatment with Investigational LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe... - December 7th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 6th, 2020
- ASH Goes Remote as CAR T-Cell Therapy Competition Heats Up - AJMC.com Managed Markets Network - December 6th, 2020
- Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition -... - December 6th, 2020
- New Drug Could Improve Effectiveness of Stem Cell Therapy - Pain News Network - December 1st, 2020
- Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise - December 1st, 2020
- Experimental stem cell gene therapy may give a new lease of life for patient with sickle cell disease - News-Medical.Net - December 1st, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 1st, 2020
- Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape - DocWire News - December 1st, 2020
- ONLINE: The UW Now - Isthmus - December 1st, 2020
- Exploring the Challenges and Opportunities of Harvesting CTCs - Technology Networks - December 1st, 2020
- Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - GlobeNewswire - December 1st, 2020
- Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study - PRNewswire - December 1st, 2020
- COVID-19 patients on some cancer therapies may be contagious for months: study - Reuters - December 1st, 2020
- Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration - GlobeNewswire - December 1st, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - GlobeNewswire - November 30th, 2020
- Coronavirus treatments and vaccines. Here are the latest developments - San Francisco Chronicle - November 30th, 2020
- Stem Cell Assay Market Research Report: Industrial Chain, Sourcing Strategy and Downstream Buyers with Forecast 2026 - Cheshire Media - November 30th, 2020
- Human Embryonic Stem Cell (hESC) Market Research Report 2020 with Manufacturing Process Analysis and Market Concentration Rate till 2026 - The Market... - November 30th, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - Philippine Canadian... - November 30th, 2020
- California's stem cell research agency looks to the future - Bond Buyer - November 26th, 2020
- Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times - November 26th, 2020
- Growing Value of Stem Cells in Medicine to Create a US$2,4 Billion Opportunity for Induced Pluripotent Stem Cell ((iPSC) - GlobeNewswire - November 26th, 2020
- Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in... - November 26th, 2020
- Unexpected discovery about stem cell immortality study - News - The University of Sydney - November 26th, 2020
- 'The hope is that is works': Coliseum participates in clinical trial for COVID-19 recovery - wgxa.tv - November 26th, 2020
- Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots... - November 26th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire - November 26th, 2020
- Our turbulent debates on medicine and morals - The Irish Catholic - November 26th, 2020
- Impact of COVID 19 on Orthopedic Regenerative Medicine Market Detailed Research Study 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation,... - November 26th, 2020
- Novartis Invests in Stem Cell Therapy for Covid - BloombergQuint - November 20th, 2020
- California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News - November 20th, 2020
- Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise - November 20th, 2020
- Study reveals how smoking worsens SARS-CoV-2 infection in the airways - UCLA Newsroom - November 20th, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 20th, 2020
- In a First, Scientists Say They've Partially Reversed a Cellular Aging Process in Humans - ScienceAlert - November 20th, 2020
- ExCellThera to establish stem cell bioproduction facility creating up to 150 jobs thanks to Government of Canada support - Canada NewsWire - November 16th, 2020
- Stanford coach's quest to save his brother: 'God, I hope this works' - Scope - November 16th, 2020
- Athersys Announces Three Appointments to Board of Directors - Business Wire - November 16th, 2020